BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

BioLineRx (BLRX) Announces Proposed ADS & Warrants OfferingFebruary 5, 2019 5:40 AM BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic CancerFebruary 4, 2019 7:00 AM